Last updated: September 9, 2026
Fluorometholone acetate is an established ophthalmic corticosteroid marketed primarily as Flarex 0.1% ophthalmic suspension. Its commercial profile is defined by an old active ingredient, limited public revenue disclosure, generic substitution risk, and competition from prednisolone acetate, dexamethasone, loteprednol etabonate, and other ocular anti-inflammatory products. The product has no meaningful biologic or biosimilar exposure. Its remaining commercial value is concentrated in brand recognition, prescriber familiarity, distribution, and the technical difficulty of manufacturing a uniform ophthalmic suspension rather than in active-ingredient exclusivity.
What is fluorometholone acetate and how is it used?
Fluorometholone acetate is a topical ophthalmic corticosteroid used to treat steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. Flarex contains fluorometholone acetate at a 0.1% concentration in an ophthalmic suspension. The product is administered topically and is not an injectable or systemic medicine.
The product competes in the prescription ophthalmic corticosteroid market. Its main clinical alternatives include:
| Product |
Active ingredient |
Form |
Primary competitive role |
| Flarex |
Fluorometholone acetate |
Ophthalmic suspension, 0.1% |
Established topical ocular steroid |
| FML |
Fluorometholone alcohol |
Ophthalmic suspension or ointment |
Same therapeutic class, different ester |
| Pred Forte |
Prednisolone acetate |
Ophthalmic suspension, 1% |
Widely used, higher-potency corticosteroid |
| Maxidex |
Dexamethasone |
Ophthalmic solution or suspension |
Broad steroid alternative |
| Lotemax and Inveltys |
Loteprednol etabonate |
Suspension or gel |
Newer corticosteroid with differentiated safety positioning |
| Eysuvis |
Loteprednol etabonate |
Ophthalmic suspension |
Short-term dry-eye flare treatment |
Fluorometholone acetate has a narrower commercial position than the largest ophthalmic steroid brands because it is an older molecule and lacks a current composition-of-matter patent franchise.
What is the FDA regulatory status of Flarex?
Flarex is an FDA-approved ophthalmic corticosteroid marketed under New Drug Application 018816. The product was originally approved decades ago, and its regulatory exclusivity has expired. FDA labeling identifies fluorometholone acetate ophthalmic suspension, 0.1%, as the active product and sets out dosing, contraindications, warnings, and administration requirements.[1]
The key regulatory characteristics are:
| Regulatory issue |
Status |
| FDA product |
Flarex ophthalmic suspension, 0.1% |
| Active ingredient |
Fluorometholone acetate |
| NDA |
018816 |
| Regulatory pathway |
Original NDA |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not identified as a current commercial protection |
| Biosimilar pathway |
Not applicable |
| OTC status |
Prescription product |
| Main regulatory risks |
Steroid-related infection, intraocular pressure elevation, delayed healing, cataract formation |
Flarex is not a biologic. A biosimilar cannot be approved for it. Any competitive product would generally enter through an abbreviated new drug application or another small-molecule pathway, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and suspension performance.
When does fluorometholone acetate lose exclusivity?
Fluorometholone acetate lost practical market exclusivity many years ago. The underlying active ingredient and original product approval date from the pre-modern patent-extension era. No current commercial value appears to depend on a live composition-of-matter patent.
The commercial exclusivity timeline is therefore best understood as follows:
| Period |
Event |
| Pre-1990s |
Original fluorometholone acetate ophthalmic products established in the U.S. |
| 1980s |
Flarex approved under NDA 018816 |
| 1990s-2000s |
Original regulatory and patent exclusivity expired |
| 2010s |
Product remained a branded niche ophthalmic steroid |
| 2020 |
Eyevance acquired by Santen, bringing Flarex into Santen's U.S. ophthalmology portfolio |
| 2020s |
Commercial protection depended mainly on brand, manufacturing, distribution, and prescription demand |
The exact expiration date of any historical formulation or method-of-use patent is less important to current market access because those rights, if any, do not create a meaningful present-day barrier to generic development. FDA Orange Book protection for Flarex should be checked against the current listing because patent entries and marketing status can change over time.[2]
What patents protect fluorometholone acetate and Flarex?
The strongest conclusion from the public product profile is that fluorometholone acetate has no meaningful active-ingredient patent estate supporting current exclusivity. The product is an old small molecule, and its main patentable opportunities would have involved:
- Specific suspension formulations
- Preservative systems
- Particle-size control
- Manufacturing processes
- Delivery devices
- Narrow method-of-use claims
- New clinical indications
These rights are weaker than a composition-of-matter patent because competitors can design around them or pursue alternative formulations. They also have limited remaining life when associated with an old ophthalmic product.
What formulation patents could affect generic entry?
An ophthalmic suspension can create technical development barriers even when patent protection is weak. A generic developer must reproduce or sufficiently match:
- Active-drug particle size and distribution
- Suspension uniformity
- Redispersibility after storage
- Drop size and container performance
- Preservative concentration
- Sterility
- Viscosity
- Stability under labeled storage conditions
- Delivered dose after shaking
These factors may increase development cost and regulatory risk, but they do not create durable exclusivity by themselves. A formulation patent would have the greatest commercial value only if it remained unexpired, covered a necessary product characteristic, and could be enforced against an ANDA applicant.
What is the Orange Book status of fluorometholone acetate?
Flarex is associated with an FDA-approved NDA rather than a biologics license application. The Orange Book is the relevant FDA reference for listed patents, therapeutic equivalence codes, and reference-listed-drug status.[2]
The commercial implications are:
- Any active Orange Book patent could support a Paragraph IV notice and Hatch-Waxman litigation.
- A generic applicant could also file a Paragraph III certification if it accepts a delayed launch until patent expiration.
- If no blocking patent is listed, the main barrier becomes FDA approval and commercial economics.
- An old ophthalmic suspension may attract fewer ANDA applicants than a high-volume tablet because development and launch economics are less attractive.
Publicly available information does not establish a current, commercially significant Orange Book patent barrier for Flarex. The product's effective protection is therefore weaker than that of newer ophthalmic medicines such as branded loteprednol products with more recent formulation and indication patents.
Which companies are challenging fluorometholone acetate?
No major, publicly documented Paragraph IV campaign against Flarex is evident from the established public record. The lack of prominent litigation is consistent with the product's relatively small market and the absence of a high-value exclusivity event.
Potential competitive categories include:
- Generic ophthalmic manufacturers
- Specialty ophthalmology companies
- Contract development and manufacturing organizations
- Companies with existing sterile ophthalmic manufacturing capacity
- Established manufacturers selling fluorometholone alcohol products
Likely commercial competitors include large generic and ophthalmic companies such as Bausch + Lomb, Alcon, Akorn-related assets, and other FDA-approved sterile ophthalmic manufacturers, although company participation and marketing status can vary by product and time.
A generic entrant does not need to challenge a strong active patent estate if no enforceable patent blocks approval. It can instead file an ANDA and compete after satisfying FDA requirements.
What litigation and settlement agreements affect Flarex?
No high-profile, publicly reported patent litigation or settlement agreement appears to define the current U.S. market for fluorometholone acetate. That distinguishes Flarex from larger ophthalmic products that have generated substantial Hatch-Waxman litigation.
The absence of a major settlement has two effects:
- There is no publicly established authorized-generic or negotiated launch date that controls market entry.
- Market timing depends more on FDA review, manufacturing readiness, and expected pricing than on a patent-settlement calendar.
Any future litigation would likely focus on formulation claims, manufacturing patents, or alleged infringement involving an Orange Book-listed patent. Such litigation would be commercially meaningful only if the asserted patent covered a product characteristic that a generic could not readily avoid.
What licensing deals involve fluorometholone acetate?
The most important disclosed transaction involving Flarex was Santen's acquisition of Eyevance Pharmaceuticals in 2020. Santen announced an upfront payment of approximately $225 million and potential milestone payments of up to approximately $35 million for the acquisition, which added Eyevance's U.S. ophthalmic portfolio to Santen's business.[3]
The transaction was not a fluorometholone-acetate-only deal. Its value reflected a portfolio that included multiple ophthalmic products and commercial infrastructure. Flarex contributed to the acquired portfolio but was not publicly assigned a standalone purchase price.
This distinction matters for valuation. The $225 million transaction value should not be treated as the implied value of Flarex. It included broader assets, including products with newer commercial profiles and potentially stronger growth prospects.
What is the financial trajectory of fluorometholone acetate?
Standalone revenue for Flarex or fluorometholone acetate is not generally disclosed in public company filings. Santen reports ophthalmology operations and product portfolios at aggregate levels rather than providing a separate Flarex income statement. As a result, precise product revenue, gross margin, prescription volume, and market share cannot be reliably calculated from public filings.
The likely financial trajectory is:
| Financial phase |
Market characteristics |
| Legacy brand period |
Stable demand from established ophthalmic prescribing |
| Portfolio-acquisition period |
Increased commercial support under Eyevance and later Santen |
| Mature-product period |
Limited unit growth, pricing sensitivity, and substitution risk |
| Generic-entry period |
Potential price erosion and share loss if an ANDA launches |
| Long-term period |
Niche branded sales supported by prescriber loyalty and supply reliability |
Revenue exposure is likely modest relative to newer specialty ophthalmology products. The main drivers are:
- Prescription volume in postoperative and inflammatory eye care
- Reimbursement and formulary placement
- Brand versus generic availability
- Product availability in ophthalmology channels
- Relative pricing against prednisolone acetate and fluorometholone alcohol
- Physician preference for the suspension's clinical profile
- Generic launch timing
Because the molecule is mature, price increases may generate temporary revenue growth but also raise substitution risk. A branded product with no meaningful patent barrier is vulnerable to payor pressure and pharmacy substitution.
How strong is the patent estate for fluorometholone acetate?
The patent estate is weak from an exclusivity perspective and moderate only from a technical-barrier perspective.
| Patent factor |
Assessment |
| Composition-of-matter protection |
Expired or commercially irrelevant |
| Core active ingredient |
Old small molecule |
| Formulation protection |
Potentially relevant but likely limited in duration and scope |
| Method-of-use protection |
Limited commercial importance |
| Manufacturing protection |
Could create execution barriers, but usually design-around risk exists |
| Orange Book leverage |
No clear current blocking estate established |
| Litigation leverage |
Low compared with newer branded ophthalmic products |
| Generic vulnerability |
Moderate to high if a viable ANDA is approved |
The principal barrier is not patent strength. It is the cost and risk of developing a sterile ophthalmic suspension for a relatively small market.
What generic entry risks exist for Flarex?
Generic entry risk is real but not necessarily imminent. The market may support only a limited number of entrants because ophthalmic suspensions require specialized manufacturing, testing, and packaging. A first generic could capture substantial pharmacy substitution volume, while subsequent entrants could intensify price erosion.
Possible launch scenarios are:
No generic launch
Flarex retains a niche branded position because the addressable market is too small or the development economics are unattractive. Revenue remains stable but likely grows slowly.
One generic entrant
The first approved generic pressures price and reduces branded volume. The brand may retain prescriptions where physicians prefer the original product or where supply reliability matters.
Multiple generic entrants
Pricing declines more sharply. Brand revenue can fall through both unit loss and net-price compression. The product may become a low-margin mature ophthalmic medicine.
Authorized-generic strategy
The brand owner or a commercial partner could launch an authorized generic to preserve channel access and capture lower-priced demand. No public evidence establishes such a strategy for Flarex.
How does fluorometholone acetate compare with competing ophthalmic steroids?
Fluorometholone acetate is commercially disadvantaged against newer products with differentiated delivery systems, indications, or safety positioning. It remains relevant because ophthalmic corticosteroids are familiar, inexpensive to prescribe relative to newer branded options, and used across routine inflammatory conditions.
| Factor |
Fluorometholone acetate |
Prednisolone acetate |
Loteprednol etabonate |
| Product maturity |
Very high |
Very high |
Newer |
| Patent strength |
Weak or expired |
Generally mature |
Stronger historical estate |
| Generic pressure |
Material |
Material |
Increasing |
| Formulation complexity |
Suspension |
Suspension |
Suspension, gel, or other systems |
| Differentiation |
Established steroid profile |
Potency and familiarity |
Safety and targeted indications |
| Commercial growth |
Limited |
Mature |
Greater potential in selected segments |
| Biosimilar risk |
None |
None |
None |
The main substitution risk comes from generic prednisolone acetate and fluorometholone alcohol, while the main branded competitive threat comes from loteprednol products.
What are the geographic markets for fluorometholone acetate?
The United States is the most commercially visible market because Flarex has an FDA-approved product and a documented U.S. commercial owner. International markets may contain fluorometholone or fluorometholone acetate products under different brand names, marketing authorization holders, dosage forms, or regulatory classifications.
Geographic value depends on:
- Local registration status
- Reimbursement
- Generic penetration
- Ophthalmology prescribing patterns
- Sterile manufacturing supply
- National price controls
- Distribution arrangements
U.S. patent and Orange Book analysis does not determine market access in Europe, Japan, China, Canada, or emerging markets. Foreign rights must be assessed by national patent registers and local regulatory databases.
What manufacturing and intellectual-property barriers remain?
Manufacturing is the principal practical barrier. The product requires sterile ophthalmic production and control of suspension characteristics. A developer must also establish container-closure integrity, microbial quality, stability, and consistent dose delivery.
The most relevant manufacturing risks are:
- Sterile filling capacity
- Suspension homogeneity
- Long-term physical stability
- Preservative performance
- Supply of ophthalmic-grade raw materials
- FDA inspection readiness
- Scale-up from laboratory to commercial batches
These barriers can delay entry and limit the number of credible manufacturers. They do not provide the same legal protection as an unexpired patent.
Key Takeaways
- Fluorometholone acetate is a mature ophthalmic corticosteroid marketed in the U.S. primarily as Flarex 0.1%.
- Flarex is associated with FDA NDA 018816.
- Core drug and regulatory exclusivity expired long ago.
- No current, commercially significant Orange Book patent barrier is established by the public record.
- No major public Paragraph IV litigation or settlement currently defines the product's market.
- Santen acquired Eyevance in 2020 for approximately $225 million upfront, plus potential milestones, but the transaction covered a broader ophthalmic portfolio.
- Standalone Flarex revenue is not publicly disclosed.
- Generic entry risk is moderate to high if an ANDA applicant accepts the manufacturing and market-size risks.
- Sterile suspension manufacturing is a more important barrier than patent protection.
- The main competitive products are prednisolone acetate, fluorometholone alcohol, dexamethasone, and loteprednol etabonate.
- The product's long-term value is likely that of a mature niche brand, not a growth asset protected by exclusivity.
FAQs about fluorometholone acetate market and patents
Is fluorometholone acetate a biologic?
No. It is a small-molecule corticosteroid administered as an ophthalmic suspension. Biosimilar regulation does not apply.
Does Flarex have active composition-of-matter patent protection?
No commercially meaningful active-ingredient patent protection is expected for this old molecule. Any current protection would more likely involve formulation, manufacturing, or delivery claims.
Can a generic company file an ANDA for Flarex?
Yes. A qualified manufacturer can pursue an ANDA if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, sterility, stability, and suspension performance.
Why is there limited generic competition for an old ophthalmic drug?
Ophthalmic suspensions require sterile manufacturing and specialized product testing. The market may not generate sufficient returns to justify development for every potential manufacturer.
Is Flarex more valuable than fluorometholone alcohol products?
Flarex may command brand value because of its specific acetate formulation and prescribing history, but its commercial advantage is constrained by the age of the product, generic substitution, and competition from other topical corticosteroids.
References
-
U.S. Food and Drug Administration. (n.d.). Flarex: Fluorometholone acetate ophthalmic suspension, 0.1% prescribing information. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
Santen Pharmaceutical Co., Ltd. (2020). Santen completes acquisition of Eyevance Pharmaceuticals. Santen corporate communications.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
Santen Pharmaceutical Co., Ltd. (2021-2024). Annual reports and securities reports. Santen Pharmaceutical Co., Ltd.
